Lexeo Therapeutics Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
75
- Stock Symbol
-
LXEO
- Investments
-
1
- Share Price
-
$3.92
- (As of Monday Closing)
Lexeo Therapeutics General Information
Description
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
Contact Information
Website
www.lexeotx.comCorporate Office
- 345 Park Avenue South, 6th Floor
- New York, NY 10010
- United States
Corporate Office
- 345 Park Avenue South, 6th Floor
- New York, NY 10010
- United States
Lexeo Therapeutics Timeline
Lexeo Therapeutics Stock Performance
As of 16-Jun-2025, Lexeo Therapeutics’s stock price is $3.92. Its current market cap is $130M with 33.2M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.92 | $3.94 | $1.45 - $19.50 | $130M | 33.2M | 1.02M | -$3.30 |
Lexeo Therapeutics Financials Summary
As of 31-Mar-2025, Lexeo Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 3,600 | 71,033 | 523,375 | |
| Revenue | 0 | 0 | 0 | 654 |
| EBITDA | (114,261) | (103,773) | (67,213) | (59,366) |
| Net Income | (109,307) | (98,333) | (66,394) | (59,277) |
| Total Assets | 125,690 | 146,942 | 139,807 | 97,076 |
| Total Debt | 9,399 | 9,924 | 11,638 | 13,482 |
Lexeo Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Lexeo Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Lexeo Therapeutics Comparisons
Industry
Financing
Details
Lexeo Therapeutics Competitors (20)
One of Lexeo Therapeutics’s 20 competitors is Solid Biosciences, a Formerly VC-backed company based in Charlestown, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Solid Biosciences | Formerly VC-backed | Charlestown, MA | ||||
| Taysha Gene Therapies | Formerly VC-backed | Dallas, TX | ||||
| Design Therapeutics | Formerly VC-backed | Carlsbad, CA | ||||
| Abeona Therapeutics | Corporation | Cleveland, OH | ||||
| Tenaya Therapeutics | Formerly VC-backed | South San Francisco, CA |
Lexeo Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Lexeo Therapeutics Patents
Lexeo Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023215308-A1 | Methods and pharmaceutical compositions for the treatment and the prevention of cardiomyopathy associated with friedreich ataxia | Pending | 01-Feb-2022 | ||
| EP-4472674-A1 | Methods and pharmaceutical compositions for the treatment and the prevention of cardiomyopathy associated with friedreich ataxia | Pending | 01-Feb-2022 | ||
| US-20250161483-A1 | Methods and pharmaceutical compositions for the treatment and the prevention of cardiomyopathy associated with friedreich ataxia | Pending | 01-Feb-2022 | A61K48/0033 |
Lexeo Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Lexeo Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Lexeo Therapeutics Acquisitions (1)
Lexeo Therapeutics’s most recent deal was a Merger/Acquisition with Stelios Therapeutics. The deal was made on 16-Jul-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Stelios Therapeutics | 16-Jul-2021 | Merger/Acquisition | Biotechnology |
Lexeo Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Lexeo Therapeutics FAQs
-
When was Lexeo Therapeutics founded?
Lexeo Therapeutics was founded in 2018.
-
Where is Lexeo Therapeutics headquartered?
Lexeo Therapeutics is headquartered in New York, NY.
-
What is the size of Lexeo Therapeutics?
Lexeo Therapeutics has 75 total employees.
-
What industry is Lexeo Therapeutics in?
Lexeo Therapeutics’s primary industry is Biotechnology.
-
Is Lexeo Therapeutics a private or public company?
Lexeo Therapeutics is a Public company.
-
What is Lexeo Therapeutics’s stock symbol?
The ticker symbol for Lexeo Therapeutics is LXEO.
-
What is the current stock price of Lexeo Therapeutics?
As of 16-Jun-2025 the stock price of Lexeo Therapeutics is $3.92.
-
What is the current market cap of Lexeo Therapeutics?
The current market capitalization of Lexeo Therapeutics is $130M.
-
Who are Lexeo Therapeutics’s competitors?
Solid Biosciences, Taysha Gene Therapies, Design Therapeutics, Abeona Therapeutics, and Tenaya Therapeutics are some of the 20 competitors of Lexeo Therapeutics.
-
What is Lexeo Therapeutics’s annual earnings per share (EPS)?
Lexeo Therapeutics’s EPS for 12 months was -$3.30.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
